Loading…
Employees: 1,800
Size Advanced Medical Solutions (AMS.L) is a United Kingdom Health Care company (Medical Specialties) with a market value of $824M, the 240th largest of 363 United Kingdom companies the cockpit tracks. Shares closed at £283.00 on 6 Nov 2026.
Performance Over six months the shares gained 13.7%, against -12.4% for the median peer and +3.6% for the United Kingdom market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 6.0% over the last twelve months (peer median +15.3%); the operating margin is 12.5% (peer median 10.1%).
Valuation It trades at 20.7× forward earnings against a peer median of 19.3× (6th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.7 points below its cost of capital (9.4% WACC).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | £234M | £229M | £178M | £126M | £124M |
| Revenue growth | — | +29% | +41% | +2% | — |
| Gross profit | £112M | £109M | £82.8M | £63.7M | £68.6M |
| EBITDA | £51.1M | £48.5M | £37.7M | £30.7M | £34.9M |
| Net income | £3.68M | £9.95M | £7.09M | £15.9M | £20.4M |
| Free cash flow | £7.95M | £21.4M | £12.7M | £10.9M | £23.3M |
| Capital expenditure | £18.0M | £12.6M | £8.74M | £9.85M | £9.96M |
| Total debt | n/a | £81.5M | £86.6M | £9.14M | £9.75M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMS.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | -6.0% | 6th highest of 21 |
| 6-month return | +13.7% | -12.4% | 5th highest of 21 |
| Distance from 52-week high | -0.5% | -31.6% | highest of 21 |
| Revenue growth (TTM) | +6.0% | +15.3% | 8th lowest of 21 |
| Operating margin | 12.5% | 10.1% | 10th highest of 21 |
| Forward P/E | 20.7× | 19.3× | 6th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 19.6% | -1.0% | 3rd most demanding of 13 |
| Growth delivered (Del g) | +21.4% | +12.1% | 4th highest of 13 |
| Hurdle (Req g minus delivered) | -1.8 pp | -16.8 pp | 3rd most demanding of 13 |
| ROIC minus cost of capital | -2.7 pp | +1.3 pp | 7th lowest of 21 |
| EV / EBITDA | 13.4× | 12.0× | 5th most expensive of 11 |
| Net debt / EBITDA | 1.4× | -0.4× | 4th most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 20.7× | 19.6% | +21.4% |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 34.7× | n/a | n/a |
| OrthoPediatrics KIDS | United States | $829M | +78% | +16% | -8% | n/a | n/a | n/a |
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | n/a | n/a | n/a |
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 164.7× | 9.2% | -10.2% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 30.0× | 21.1% | +24.2% |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | n/a | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $798M | -27% | +40% | 10% | 12.5× | -8.0% | +6.6% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 15.9× | 5.5% | +105.8% |
| Standard Engineering Technology SETL.NS | India | $796M | +164% | +26% | 13% | n/a | n/a | n/a |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $784M | -25% | +35% | 21% | 17.8× | -2.1% | +23.5% |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 20.3× | n/a | n/a |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 19.8× | 0.1% | +15.6% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 10.1× | -10.5% | +12.4% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |